Sutro Biopharma (STRO.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

Sutro Biopharma Begins Phase 1 Clinical Trial of STRO-004

13:00

Nov13

Piper Sandler Analyst Reiterates Buy Rating on Sutro Biopharma

11:52

Nov7

H.C. Wainwright Analyst Maintains Hold Rating for Sutro Biopharma

12:11

Sutro Biopharma released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 9.693 M (forecast USD 9.129 M), actual EPS USD -6.6993 (forecast USD -3.9745)

04:00

Sutro Biopharma released FY2025 9 Months Earnings on November 6 (EST), with actual revenue of USD 90.84 M and EPS of USD -1.7199

04:00

Nov3

Sutro Biopharma Inc. to showcase next-generation antibody drug conjugates preclinical data

13:02

Schedules & Filings

Schedules

Filings

Dec3

Reverse Stock Split(EST)

1-for-10 Reverse Stock Split

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 9.693 M, Net Income -56.86 M, EPS -6.6993

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 63.75 M, Net Income -11.5 M, EPS -1.3595

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change